According to the percentages of CD4+CD8−, CD4−CD8+ and DN iNKT cell subsets of T cells in the MM patients with Stage A/B or C bone disease (Table 4), the percentage of CD4−CD8+ iNKT cells was significantly lower in the patients with Stage C bone disease than those with Stage A/B bone disease and HCs (P = .029 and P < .001, respectively; Figure 1G). This evidence concerns the gene CD4 and Miyoshi myopathy.